Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dollar Tree, Inc. (DLTR), Questcor Pharmaceuticals, Inc. (QCOR): Three Stocks to Buy After Earnings

Page 1 of 2

Earnings can dictate the direction of a stock for the following three months. Investors pay close attention to earnings and often make emotional decisions based on the performance of a stock post-earnings. However, the performance of a stock following earnings should never be the first line of research, rather the last. With that being said, I am looking at three stocks that I believe are a buy right now based on strong earnings, regardless of stock performance.

Dollar Tree, Inc. (NASDAQ:DLTR)

Back in December I said to buy Dollar Tree and that its operational problems would not last. Turns out I was right, as the stock has posted gains of more than 11% following earnings. The company posted Q4 earnings that saw revenue increase 15.4% year-over-year (yoy), beating expectations but also beating on the bottom line. The company improved its operating margins by 70 basis points and saw comparable store sales increase 2.4%. Overall, it was a great quarter, and the stock responded accordingly to both the earnings and its bullish guidance.

Dollar Tree, Inc. (NASDAQ:DLTR) has seen a nice bounce following earnings but at $45.40 it is still more than $10 off its 52-week highs. In terms of valuation, I’d say it is fairly valued. The company is trading with a forward P/E ratio of 14.0 and a price/sales below 1.50. In my opinion, DLTR is now a buy. The psychological perception of the company has been shifted from pessimism to optimism, and sometimes this is more important than fundamental performance. As a result, I believe the stock could see a large move upwards over the next three months, and therefore I would watch it closely.

Big 5 Sporting Goods Corporation (NASDAQ:BGFV)

Shares of Big 5 immediately popped almost 8% after the company reported earnings on Tuesday. However, as the session progressed it trended lower, and has since returned gains of just 3%. The company is a competitor of both Dicks Sporting Goods and Hibbett Sports, but looks to be the best value in its space. This is a company that executed to perfection during its quarter. The company beat on both the top and bottom line, it raised guidance, and raised its dividend 33% to carry a forward yield of 2.64%.

Big 5 trades with a price/sales of 0.36 and a forward P/E ratio of 13.80, making it cheap on these two metrics alone. The big problem with the company over the last three years has been margins. However, in 2012 the company made major strides at improving these margins, and according to its guidance of $0.18-$0.24 per share (compared to expectations of $0.08) it looks as though these improvements will continue. Therefore, I say it’s time to buy this under-the-radar and undervalued stock.

Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR)

The biotechnology company Questcor Pharmaceuticals has traded virtually flat since announcing earnings on Wednesday, yet the company posted a huge beat over expectations. The company announced revenue of $160.5 million ($18 million better than consensus) and an EPS of $1.09 ($0.12 better than the consensus) due to strong growth from its drug Acthar. These numbers represent growth of 113% yoy, as Acthar prescriptions grew in the treatment of nephrotic syndrome, MS relapses, and infantile spasms.

It has been a tough year for Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR). The company was attacked by famed short-seller Andrew Left from Citron Research and then had to adjust when health insurers cut coverage on its drug. The main question surrounding this company is sustainability of Acthar, as this is a company that relies on just one product’s success. However, Questcor recently acquired a clinical stage company to create diversification and with more than 100% growth it’s obvious that these concerns are not currently affecting the company. Therefore, with a forward P/E ratio of just 6.64 and a price/sales of 3.79 I believe QCOR is a must buy, as a company that just keeps on growing.

Page 1 of 2
Loading Comments...